PARTNER 3 Trial - Aortic Valve-in-Valve

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.

Also called NCT03003299

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 125 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03003299
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03003299. Allocation not applicable; no masking; primary purpose treatment. Start 2017-01-05 (actual); primary completion 2033-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PARTNER 3 Trial - Aortic Valve-in-Valve
Condition
Aortic Stenosis
Condition
Aortic Stenosis, Severe
Intervention (Device)
Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct03003299
Content hash
6f11bfcf9b6eb45e9f8a81f4c541db761f237217a4e9df57388e18c96e9fd7b2